An Open-Label, Randomized, Phase II Trial of Durvalumab (MEDI4736) With or Without Bavituximab in Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer

Trial Profile

An Open-Label, Randomized, Phase II Trial of Durvalumab (MEDI4736) With or Without Bavituximab in Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer

Suspended
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2016

At a glance

  • Drugs Bavituximab (Primary) ; Durvalumab (Primary)
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Sponsors Peregrine Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2016 Trial design presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 09 Mar 2016 According to a Peregrine Pharmaceuticals media release, due to setback development in the SUNRISE trial, the companies (Peregrine and AstraZeneca) are currently working together to identify the optimal path forward for demonstrating potential mechanistic synergies between bavituximab and durvalumab in different patient populations. The expected timing of initiation of this trial will be determined upon finalization of its trial design.
    • 09 Mar 2016 According to a Peregrine Pharmaceuticals media release, status changed from not yet recruiting to suspended.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top